---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-038535"
form_type: "8-K/A"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2026-10-05T11:21:13+00:00"
generated_at: "2026-10-12T14:44:12.293875+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Processa's Vidya acquisition adds BTK inhibitor VT7208 plus a $200M private placement

## Summary
- On July 28, 2026 Processa acquired Vidya Therapeutics; VT7208, an oral CNS-penetrant BTK inhibitor, is now the lead asset in food allergy, chronic spontaneous urticaria and MS.
- Received $200M gross proceeds from private placement of non-voting convertible preferred stock; investors include Bain Capital Life Sciences, Janus Henderson, RA Capital and Cormorant.
- Phase 1 data: 5 mg single dose achieved >95% BTK target occupancy at 4 hours and >99% peak, sustained ~48 hours; 10 mg MAD dose hit 100% occupancy.
- Phase 1 trial in 24 healthy volunteers (5-60 mg) showed no dose-limiting toxicities, no serious adverse events, no treatment-related discontinuations and no liver-safety signal; DILI-risk score 2.1.
- Founder Sheila Gujrathi, M.D., who led ocrelizumab (Ocrevus) development at Roche, heads the team; company also continues legacy assets PCS499, PCS12852 and PCS11T.

## SEC filing metadata
- accession: 0001140361-26-038535
- form_type: 8-K/A
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2026-10-05T11:21:13+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000114036126038535/0001140361-26-038535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000114036126038535/ef20083140_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-038535
- JSON: https://secwatch.observer/filing/0001140361-26-038535.json
- Plain text: https://secwatch.observer/filing/0001140361-26-038535.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.